Palovarotene Patent Expiration
Palovarotene is Used for reducing heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva. It was first introduced by Ipsen Biopharmaceuticals Inc
Palovarotene Patents
Given below is the list of patents protecting Palovarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sohonos | US10864194 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US11622959 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US12138245 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US12201614 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US12458626 | Methods For Treating Heterotopic Ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US10292954 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US12023312 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US9314439 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US9789074 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Palovarotene's patents.
Latest Legal Activities on Palovarotene's Patents
Given below is the list recent legal activities going on the following patents of Palovarotene.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| FDA Final Eligibility Letter | 18 Sep, 2025 | US10292954 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US11622959 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US10864194 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US9314439 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2025 | US9789074 |
| transaction for FDA Determination of Regulatory Review Period | 18 Dec, 2024 | US9314439 |
| transaction for FDA Determination of Regulatory Review Period | 18 Dec, 2024 | US10864194 |
| transaction for FDA Determination of Regulatory Review Period | 18 Dec, 2024 | US11622959 |
| transaction for FDA Determination of Regulatory Review Period | 18 Dec, 2024 | US10292954 |
| transaction for FDA Determination of Regulatory Review Period | 30 Oct, 2024 | US10864194 |
Palovarotene's Family Patents
